Skip to main content

Table 3 Treatment effect of immune checkpoint inhibitors after pemetrexed treatment failure

From: High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study

Efficacy Long-term
administration
( n = 11)
Intermediate-term
administration
( n = 16)
Short-term
administration
( n = 55)
Cycles 6.1 ± 8.5 5.6 ± 3.2 6.2 ± 8.3
PFS (month) 5.5 ± 6.9 3.8 ± 2.7 3.4 ± 4.4
  1. Data are presented as mean ± SD
  2. PFS progression free survival